Immune checkpoint inhibitors and targeted therapies, two new class of drugs for treatment of metastatic melanoma, have not been compared in randomized controlled trials (RCT). We quantitatively summarized the evidence and compared immune and targeted therapies in terms of both efficacy and toxicity.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jXlAUy
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Many different quantitative techniques have been developed to either assess Environmental Justice (EJ) issues or estimate exposure and dose ...
-
Leddsmerter kan ha mange årsaker. Traumatiske, immunologiske og infeksiøse lidelser må vurderes. En god anamnese kan sette oss på rett spor...
-
Outcomes of Drug-Induced Sleep Endoscopy-Directed Surgery for Pediatric Obstructive Sleep Apnea. Otolaryngol Head Neck Surg. 2017 Nov ...
-
Evidence-Based Medicine: Cleft Palate. Plast Reconstr Surg. 2017 Jan;139(1):191e-203e Authors: Woo AS Abstract LEARNING OBJECTIVES:...
-
Apple, Facebook, Google and Microsoft claim the president’s ban on people from seven Muslim-majority countries inflicts "substantial ha...
-
Trends in Otolaryngology Consultation Patterns at an Academic Quaternary Care Center. JAMA Otolaryngol Head Neck Surg. 2017 Jan 05;: ...
-
Abstract An intriguing piece of evidence for the inflammatory story of type 2 diabetes has come to the light. A recent study by Okin and co...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου